Scroll to top

Clinical

CLINUVEL
Posted by CLINUVEL
March 24, 2021

Media Release - CLINUVEL Expands DNA Repair Program

SCENESSE® (afamelanotide 16mg) to be evaluated in xeroderma pigmentosum variant (XP-V) CLINUVEL...

Read More
CLINUVEL
Posted by CLINUVEL
March 24, 2021

SCENESSE® To Be Evaluated in Xeroderma Pigmentosum Variant (XPV)

CLINUVEL today announced that it has reached agreement with clinical and academic...

Read More
CLINUVEL
Posted by CLINUVEL
February 11, 2021

SCENESSE® Granted Market Access In Israel

CLINUVEL today announced that SCENESSE® (afamelanotide 16mg) has been added to the...

Read More
CLINUVEL
Posted by CLINUVEL
November 30, 2020

SCENESSE® DNA REPAIR STUDY IN HEALTHY VOLUNTEERS APPROVED

Melbourne, Australia, 30 November 2020 CLINUVEL PHARMACEUTICALS LTD today announced that it...

Read More
CLINUVEL
Posted by CLINUVEL
October 28, 2020

Afamelanotide for Acute Stroke Patients

EXECUTIVE SUMMARY • World’s first pilot study (CUV801) to evaluate afamelanotide in...

Read More
CLINUVEL
Posted by CLINUVEL
October 27, 2020

Media Release – CLINUVEL to Trial Innovative Drug in Stroke

The drug afamelanotide will be used for the first time in patients...

Read More
CLINUVEL
Posted by CLINUVEL
October 27, 2020

Media Release – TGA approves Australian drug to protect patients from light and sun

New Australian-developed drug approved by TGA for metabolic disorder erythropoietic protoporphyria (EPP)...

Read More
CLINUVEL
Posted by CLINUVEL
October 26, 2020

Update: SCENESSE® in DNA Repair

CLINUVEL PHARMACEUTICALS LTD provided today a clinical update on the use of...

Read More
CLINUVEL
Posted by CLINUVEL
October 7, 2020

SCIENTIFIC COMMUNIQUÉ VI

Ultraviolet Radiation Damage and Oxidative Stress in Skin Cancer. October 2020 Introduction...

Read More
CLINUVEL
Posted by CLINUVEL
September 14, 2020

Media Release - First patient dosed in SCENESSE® DNA Repair Program

Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment In the search for a...

Read More
CLINUVEL
Posted by CLINUVEL
September 14, 2020

First patient dosed in SCENESSE® DNA Repair Program

Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment CLINUVEL PHARMACEUTICALS LTD today announced...

Read More
CLINUVEL
Posted by CLINUVEL
September 10, 2020

Media Release (ASX) - CLINUVEL progresses innovative DNA Repair Program

Drug tested to protect skin and regenerate DNA, firstly in XP patients...

Read More
CLINUVEL
Posted by CLINUVEL
September 10, 2020

Media Release – New drug to repair damaged skin and reduce skin cancer risk

Figure 1: CLINUVEL’s DNA Repair Program aims to confirm that intervention with...

Read More
CLINUVEL
Posted by CLINUVEL
September 10, 2020

SCENESSE® in DNA Repair

CLINUVEL to confirm cellular DNA repair in rare disease xeroderma pigmentosum (XP)...

Read More
CLINUVEL
Posted by CLINUVEL
July 13, 2020

Media Release - Second Afamelanotide Formulation

PRÉNUMBRA®- CLINUVEL’S SECOND AFAMELANOTIDE FORMULATION Drug to be evaluated in patients with...

Read More
CLINUVEL
Posted by CLINUVEL
July 13, 2020

PRÉNUMBRA® – New Liquid Afamelanotide Presentation

EXECUTIVE SUMMARY • PRÉNUMBRA® non-solid dosage form of afamelanotide • Active life-cycle...

Read More
We use cookies to give you the best experience.